Skip to content
HowShorted

Zentalis Pharmaceuticals, Inc. short interest in 2021

In 2021, Zentalis Pharmaceuticals, Inc.'s disclosed short interest ran from 6.58% of shares outstanding on 15 Jan 2021 to 7.59% on 31 Dec 2021, a change of +1.01 percentage points. The year's high was 8.14% on 31 Mar 2021 and its low 4.99% on 31 Aug 2021, averaging 6.26% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.81 days on 29 Oct 2021. Full history: Zentalis Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Zentalis Pharmaceuticals, Inc. in 2021

2021 in figures

Start of year
6.58% (15 Jan 2021)
End of year
7.59% (31 Dec 2021)
Change
+1.01 pp
High
8.14% (31 Mar 2021)
Low
4.99% (31 Aug 2021)
Average
6.26%
Highest days to cover
19.81 (29 Oct 2021)
SEC filings marked
8

Every report in 2021

Zentalis Pharmaceuticals, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20216.58%9.65
29 Jan 20216.48%10.44
12 Feb 20215.48%14.37
26 Feb 20216.79%11.17
15 Mar 20216.72%10.69
31 Mar 20218.14%12.5410-K filed, results (8-K)
15 Apr 20217.72%8.38
30 Apr 20215.44%7.95
14 May 20216.16%8.16
28 May 20216.03%9.6710-Q filed, results (8-K)
15 Jun 20215.85%8.48
30 Jun 20215.73%5.25
15 Jul 20215.56%7.69
30 Jul 20215.75%10.37
13 Aug 20215.16%14.5710-Q filed, results (8-K)
31 Aug 20214.99%8.87
15 Sep 20215.12%10.26
30 Sep 20215.53%6.58
15 Oct 20216.04%11.47
29 Oct 20216.34%19.81
15 Nov 20216.49%13.7810-Q filed, results (8-K)
30 Nov 20216.91%14.39
15 Dec 20217.74%10.17
31 Dec 20217.59%12.43

See also: Zentalis Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.